These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36199185)

  • 1. BI6727, a polo-like kinase 1 inhibitor, synergizes with gefitinib to suppress hepatocellular carcinoma cells via a G2/M arrest mechanism.
    Zhou Q; Chen T
    Pharmazie; 2022 Sep; 77(7):230-235. PubMed ID: 36199185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest.
    Li QZ; Chen YY; Liu QP; Feng ZH; Zhang L; Zhang H
    Phytomedicine; 2024 Apr; 126():155177. PubMed ID: 38412667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.
    Riantana H; Waenphimai O; Mahalapbutr P; Karnchanapandh K; Vaeteewoottacharn K; Wongkham S; Sawanyawisuth K
    Pathol Res Pract; 2023 Aug; 248():154678. PubMed ID: 37454493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
    Yang AL; Wu Q; Hu ZD; Wang SP; Tao YF; Wang AM; Sun YX; Li XL; Dai L; Zhang J
    Toxicol Appl Pharmacol; 2021 Nov; 431():115739. PubMed ID: 34619160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
    Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
    World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaempferol from Alpinia officinarum hance induces G2/M cell cycle arrest in hepatocellular carcinoma cells by regulating the ATM/CHEK2/KNL1 pathway.
    Li X; Zhou M; Zhu Z; Wang Z; Zhang X; Lu L; Xie Z; Wang B; Pan Y; Zhang J; Xu J
    J Ethnopharmacol; 2024 Oct; 333():118430. PubMed ID: 38857680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.
    Sun WJ; Huang H; He B; Hu DH; Li PH; Yu YJ; Zhou XH; Lv Z; Zhou L; Hu TY; Yao ZC; Lu MD; Shen X; Zheng ZQ
    Biochem Pharmacol; 2017 Mar; 127():90-100. PubMed ID: 28012958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
    Chen E; Pei R
    J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
    Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
    Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4883-4894. PubMed ID: 38165424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
    Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
    Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
    Cui SX; Zhang YS; Chu JH; Song ZY; Qu XJ
    Cell Physiol Biochem; 2015; 35(1):201-12. PubMed ID: 25591763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
    Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
    Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
    Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
    Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.
    Liao YJ; Bai HY; Li ZH; Zou J; Chen JW; Zheng F; Zhang JX; Mai SJ; Zeng MS; Sun HD; Pu JX; Xie D
    Cell Death Dis; 2014 Mar; 5(3):e1137. PubMed ID: 24651440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.